Remicade (infliximab) (Rheumatoid Arthritis) Market Size, Share, Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast To 2023 Summary Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints. It affects over seven million individuals in the 10MM covered in this report (US, France, Germany, Italy, Spain, UK, Japan, Australia, China, and India) and the prevalence is expected to grow to just over 8.5 million individuals by 2023. The anti-TNFs have been effective in treating the signs and symptoms of RA and inhibiting progression to erosive bone disease. However, the landscape is quickly changing with the introduction of biosimilars, novel biologics, and a class of oral therapies known as JAK inhibitors, all of which will change the market dynamics between 2013 and 2023. With the anti-TNFs as extremely effective therapies for RA, the market is extremely competitive for new entrants and will undergo further pressure as biosimilars are approved and launch. Remicade (infliximab) was originally developed as a result of a collaboration between two professors at NYU Langone Medical Center and Centocor Ortho Biotech (acquired by Janssen Biotech, a subsidiary of J&J) (NYU Langone Medical Center, press release, August 12, 2005). It is first-generation TNF inhibitor consisting of a chimeric IgG1 mAb that is specific for TNFa. Remicade binds to TNFa with high affinity, neutralizing the effects of this cytokine, thus preventing synovial inflammation and decreasing joint erosion in patients with RA. Read Complete Report with TOC: http://www.radiantinsights.com/research/remicadeinfliximab-rheumatoid-arthritis-forecast-and-market-analysis-to-2023 Scope - Overview of Rheumatoid Arthritis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on Remicade (infliximab) including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for Remicade (infliximab) for the top 10 countries from 2013 to 2023. - Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Australia, China and India. Reasons To Buy - Understand and capitalize by identifying products that are most likely to ensure a robust return. - Stay ahead of the competition by understanding the changing competitive landscape for Rheumatoid Arthritis. - Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.
- Make more informed business decisions from insightful and in-depth analysis of Remicade (infliximab) performance. - Obtain sales forecast for Remicade (infliximab) from 2013-2023 in top 10 countries (the US, France, Germany, Italy, Spain, the UK and Japan, Australia, China and India). Table Of Content: Table of Contents 6 1.1 List of Tables 8 1.2 List of Figures 8 2 Introduction 9 2.1 Catalyst 9 2.2 Related Reports 10 2.3 Upcoming Related Reports 13 3 Disease Overview 14 3.1 Etiology and Pathophysiology 14 3.1.1 Etiology 14 3.1.2 Pathophysiology 14 3.2 Symptoms 19 3.3 Prognosis 20 3.4 Quality of Life 20 Browse Our More Pharmaceuticals & Healthcare Related Reports @ http://www.radiantinsights.com/catalog/pharmaceuticals-and-healthcare 4 Disease Management 21 4.1 Diagnosis and Treatment Overview 21 4.1.1 Diagnosis 21 4.1.2 Treatment Guidelines 23 4.1.3 Leading Prescribed Drugs for the Treatment of RA 33 4.1.4 Clinical Practice 34 5 Competitive Assessment 40 5.1 Overview 40 6 Remicade (infliximab) 42 6.1 Overview 42 6.2 Efficacy 44 6.3 Safety 46 6.4 SWOT Analysis 47 6.5 Forecast 47 7 Appendix 49 7.1 Bibliography 49
7.2 Abbreviations 54 7.3 Methodology 57 7.4 Forecasting Methodology 57 7.4.1 Diagnosed RA Patients 57 7.4.2 Percentage of Drug-Treated Patients 58 7.4.3 General Pricing Assumptions 58 7.4.4 Individual Drug Assumptions 60 7.4.5 Generic and Biosimilar Erosion 60 To View sample pages click on: http://www.radiantinsights.com/research/remicadeinfliximab-rheumatoid-arthritis-forecast-and-market-analysis-to-2023#tabs-4 7.5 Primary Research - KOLs Interviewed for This Report 61 7.6 Primary Research - Prescriber Survey 63 7.7 About the Authors 64 7.7.1 Analyst 64 7.7.2 Reviewer 64 7.7.3 Therapy Area Director 64 7.7.4 Global Head of Healthcare 65 7.8 About GlobalData 66 7.9 Disclaimer 66 About Us Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of Ancillary services such as, research partnerships/ tie-ups and customized research solutions. Media Contact: Michelle Thoras Corporate Sales Specialist, USA Radiant Insights, Inc Phone: 1-415-349-0054 Toll Free: 1-888-202-9519 Email: sales@radiantinsights.com Website: Radiant Insights Visit Our Blog: radiantri.blogspot.com